ADMA Biologics (ADMA) PT Raised to $14 at H.C. Wainwright

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. JNJ
6. PLTR
7. HUM
8. CSCO
9. KTOS
10. NVDA

Go back to ADMA Biologics (ADMA) PT Raised to $14 at H.C. Wainwright

ADMA Biologics (ADMA) Reports Prelim. Q4 & FY19 Revenues Above Consensus; Offers FY20 Strategic Outlook

January 9, 2020 7:10 AM EST

ADMA Biologics, Inc. (NASDAQ: ADMA) today announced its preliminary unaudited fourth quarter and full year 2019 revenues. The Company also provided updates on the commercial launches of its marketed intravenous immunoglobulin (IVIG) products, BIVIGAM® and ASCENIV, as well as introduced its 2020 strategic outlook.

Fourth Quarter and Full Year 2019 Highlights

Achieved fourth quarter 2019 preliminary unaudited total revenues of $11.9 million, compared to $4.1 million during the fourth quarter of 2018, reflecting a 193% increase over fourth quarter 2018Full year 2019 preliminary unaudited total revenues of $29.2 million, compared to $17.0 million for the full year 2018, reflecting a... More